106 related articles for article (PubMed ID: 12113140)
1. Recent advances in the management of squamous cell carcinoma of the head and neck.
Kim KB; Khuri FR; Shin DM
Expert Rev Anticancer Ther; 2001 Jun; 1(1):99-110. PubMed ID: 12113140
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
3. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
4. Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer.
Marur S; Forastiere AA
Curr Opin Oncol; 2010 May; 22(3):206-11. PubMed ID: 20216313
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for head and neck cancer.
Rhee JC; Khuri FR; Shin DM
Expert Opin Emerg Drugs; 2004 May; 9(1):91-104. PubMed ID: 15155138
[TBL] [Abstract][Full Text] [Related]
6. Expanding role of the medical oncologist in the management of head and neck cancer.
Choong N; Vokes E
CA Cancer J Clin; 2008; 58(1):32-53. PubMed ID: 18096865
[TBL] [Abstract][Full Text] [Related]
7. Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy.
Posner MR
Oncologist; 2005; 10 Suppl 3():11-9. PubMed ID: 16368867
[TBL] [Abstract][Full Text] [Related]
8. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
10. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.
Bernier J
Hematol Oncol Clin North Am; 2008 Dec; 22(6):1193-208, ix. PubMed ID: 19010268
[TBL] [Abstract][Full Text] [Related]
12. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
Finnegan V; Parsons JT; Greene BD; Sharma V
Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
[TBL] [Abstract][Full Text] [Related]
14. Postoperative concurrent chemoradiotherapy with mitomycin in advanced squamous cell carcinoma of the head and neck: results from three prospective randomized trials.
Rewari AN; Haffty BG; Wilson LD; Son YH; Joe JK; Ross DA; Papac RJ; Sasaki CT; Fischer JJ
Cancer J; 2006; 12(2):123-9. PubMed ID: 16630403
[TBL] [Abstract][Full Text] [Related]
15. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
16. The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck.
Awada A; Ismael G
Curr Opin Oncol; 2007 May; 19(3):177-9. PubMed ID: 17414633
[TBL] [Abstract][Full Text] [Related]
17. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
Gilbert J; Argiris A
Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
[TBL] [Abstract][Full Text] [Related]
18. Development of targeted therapy for squamous cell carcinomas of the head and neck.
Burgos-Tiburcio A; Santos ES; Arango BA; Raez LE
Expert Rev Anticancer Ther; 2011 Mar; 11(3):373-86. PubMed ID: 21417852
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer.
Le QT; Giaccia AJ
Clin Cancer Res; 2003 Oct; 9(12):4287-95. PubMed ID: 14555497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
